Metabolism as a key to histone deacetylase inhibition

Critical Reviews in Biochemistry and Molecular Biology

Volumn 46, Issue 3, 2011, Pages 181-199

  Rajendran, Praveen ^a   Williams, David E ^a   Ho, Emily ^a   Dashwood, Roderick H ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

cancer; chemoprevention; chemoprotection; chromatin remodeling; Epigenetics; HDAC; protein acetylation

Indexed keywords

3,3' DIINDOLYLMETHANE; ACETYLCYSTEINE; ALLICIN; ALLIIN; BUTYRIC ACID; DIALLYL DISULFIDE; DIALLYL TRISULFIDE; DIMETHYL SULFIDE; GLUCORAPHANIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; INDOLE DERIVATIVE; MESALAZINE; METHYLSELENOCYSTEINE; ORGANOSELENIUM DERIVATIVE; ORGANOSULFUR DERIVATIVE; PHENETHYL ISOTHIOCYANATE; POLYPHENOL DERIVATIVE; ROMIDEPSIN; SELENOMETHIONINE; SHORT CHAIN FATTY ACID; THIOL; TRIBUTYRIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APPLE JUICE; CHEMOPROPHYLAXIS; COLON CANCER; DIABETES MELLITUS; DIETARY INTAKE; DRUG BINDING; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; METABOLISM; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ACETYLATION; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEPSIPEPTIDES; EPIGENESIS, GENETIC; EPIGENOMICS; FATTY ACIDS, VOLATILE; FLAVONOIDS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; ISOTHIOCYANATES; NEOPLASMS; ORGANOSELENIUM COMPOUNDS; PHENOLS; POLYPHENOLS; PRODRUGS; SULFUR COMPOUNDS;

EID: 79956362344     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2011.557713     Document Type: Review

References (230)

1. Abbas A, Gupta S. 2008. The role of histone deacetylases in prostate cancer. Epigenetics 3:300-309.
2. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. 2009. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 40:464-473.
3. Aggarwal BB. 2010. Targeting infammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173-199.
4. Aggarwal BB, Ichikawa H. 2005. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4:1201-1215. (Pubitemid 41365390)
5. Ahmad A, Sakr WA, Rahman KM. 2010. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 11:652-666.
6. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH, Smoot D. 2009. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 54:2109-2117.
7. Assisi RF; GISDI Study Group. 2008. Combined butyric acid/ mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 54:231-238.
8. Balakrishnan L, Milavetz B. 2010. Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Biol 45:440-452.
9. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734. (Pubitemid 41040705)
10. Bang MH, Chio OS, Kim WK. 2007. Soy oligosaccharide increases fecal bifdobacteria counts, short-chain fatty acids, and fecal lipid concentrations in young Korean women. J Med Food 10:366-370.
11. Barnes PJ. 2010a. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 19:330-338.
12. Barnes PJ. 2010b. Mechanisms and resistance in glucocorticoid control of infammation. J Steroid Biochem Mol Biol 120:76-85.
13. Barnes PJ. 2009. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71:451-464.
14. Bar-Sela G, Epelbaum R, Schafer M. 2010. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17:190-197.
15. Batra S, Sahu RP, Kandala PK, Srivastava SK. 2010. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnof in human pancreatic carcinoma cells. Mol Cancer Ter 9:1596-1608.
16. Biancotto C, Frigè G, Minucci S. 2010. Histone modifcation therapy of cancer. Adv Genet 70:341-386.
17. Bird AR, Vuaran MS, King RA, Noakes M, Keogh J, Morell MK, Topping DL. 2008. Wholegrain foods made from a novel high-amylose barley variety (Himalaya 292) improve indices of bowel health in human subjects. Br J Nutr 99:1032-1040.
18. Bofa LC, Vidali G, Mann RS, Allfrey VG. 1978. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253:3364-3366. (Pubitemid 8349780)
19. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A. 2008. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283:26694-26704.
20. Brunetti-Pierri N, Lanpher B, Erez A, Ananieva EA, Islam M, Marini JC, Sun Q, Yu C, Hegde M, Li J, Wynn RM, Chuang DT, Hutson S, Lee B. 2010. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet 20:631-640.
21. Bush EW, McKinsey TA. 2010. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 106:272-284.
22. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giufrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E. 2008. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 33:2444-2471.
23. Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429:273-282.
24. Cheung KL, Kong AN. 2010. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12:87-97.
25. Chi P, Allis CD, Wang GG. 2010. Covalent histone modifcations- miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10:457-469.
26. Cho YS, Whitehead L, Li J, Chen CH, Jiang L, Vögtle M, Francotte E, Richert P, Wagner T, Traebert M, Lu Q, Cao X, Dumotier B, Fejzo J, Rajan S, Wang P, Yan-Neale Y, Shao W, Atadja P, Shultz M. 2010. Conformational refnement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J Med Chem 53:2952-2963.
27. Chou CJ, Herman D, Gottesfeld JM. 2008. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 283:35402-35409.
28. Choudhury M, Shukla SD. 2008. Surrogate alcohols and their metabolites modify histone H3 acetylation: involvement of histone acetyl transferase and histone deacetylase. Alcohol Clin Exp Res 32:829-839. (Pubitemid 351589386)
29. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. 2010. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501:79-90.
30. Clarke JD, Dashwood RH, Ho E. 2008. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269:291-304.
31. Colussi C, Illi B, Rosati J, Spallotta F, Farsetti A, Grasselli A, Mai A, Capogrossi MC, Gaetano C. 2010. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res 62:3-10.
32. Corfe BM, Williams EA, Bury JP, Riley SA, Croucher LJ, Lai DY, Evans CA. 2009. A study protocol to investigate the relationship between dietary fbre intake and fermentation, colon cell turnover, global protein acetylation and early carcinogenesis: the FACT study. BMC Cancer 9:332.
33. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums. 2009. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10:99-106.
34. Dashwood RH, Ho E. 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17:363-369. (Pubitemid 47369168)
35. Dashwood RH, Myzak MC, Ho E. 2006. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27:344-349. (Pubitemid 43159888)
36. Davis CD, Ross SA. 2007. Dietary components impact histone modifcations and cancer risk. Nutr Rev 65:88-94. (Pubitemid 351804383)
37. Davis CD, Ross SA. 2008. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev 66:477-482.
38. Delage B, Dashwood RH. 2008. Dietary manipulation of histone structure and function. Annu Rev Nutr 28:347-366.
39. Delage B, Dashwood RH. 2009a. Targeting the epigenome with dietary agents. In: Surh Y-J, ed. Dietary Modulation of Cell Signaling Pathways. Boca Raton, FL: CRC Press, Vol. 13, pp. 337-369.
40. Delage B, Dashwood RH. 2009b. Nutrients, histone modifcations, and chromatin remodeling in chronic infammation. In: Choi S-W, Frisco S, eds. Nutrients and Epigenetics. Boca Raton, FL: CRC Press, Vol. 6, pp. 127-154.
41. Dempe JS, Pfeifer E, Grimm AS, Metzler M. 2008. Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells. Mol Nutr Food Res 52:1074-1081.
42. Denu JM. 2007. Vitamins and aging: pathways to NAD+ synthesis. Cell 129:453-454. (Pubitemid 46660982)
43. Desai D, Salli U, Vrana KE, Amin S. 2010. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 20:2044-2047.
44. Dietz KC, Casaccia P. 2010. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 62:11-17.
45. Ding H, Dolan PJ, Johnson G V. 2008. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106:2119-2130.
46. Dinkova-Kostova AT, Talalay P. 2008. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 52 (Suppl 1):S128-S138.
47. Dittenhafer-Reed KE, Feldman JL, Denu JM. 2010. Catalysis and mechanistic insights into sirtuin activation. Chembiochem 12:281-289.
48. Donmez G, Guarente L. 2010. Aging and disease: connections to sirtuins. Aging Cell 9:285-290.
49. Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW. 2008. Structural studies of human histone deacetylase 8 and its site-specifc variants complexed with substrate and inhibitors. Biochemistry 47:13554-13563.
50. Druesne N, Pagniez A, Mayeur C, Tomas M, Cherbuy C, Duée PH, Martel P, Chaumontet C. 2004a. Diallyl disulfde (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25:1227-1236. (Pubitemid 38968051)
51. Druesne N, Pagniez A, Mayeur C, Tomas M, Cherbuy C, Duée PH, Martel P, Chaumontet C. 2004b. Repetitive treatments of colon HT-29 cells with diallyl disulfde induce a prolonged hyperacetylation of histone H3 K14. Ann N Y Acad Sci 1030:612-621. (Pubitemid 40378960)
52. Druesne-Pecollo N, Chaumontet C, Latino-Martel P. 2008. Diallyl disulfde increases histone acetylation in colon cells in vitro and in vivo. Nutr Rev 66 (Suppl 1):S39-S41.
53. Druesne-Pecollo N, Chaumontet C, Pagniez A, Vaugelade P, Bruneau A, Tomas M, Cherbuy C, Duée PH, Martel P. 2007. In vivo treatment by diallyl disulfde increases histone acetylation in rat colonocytes. Biochem Biophys Res Commun 354:140-147. (Pubitemid 46137958)
54. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly J F, Ricker JL, Richon VM, Frankel SR. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39. (Pubitemid 46053039)
55. Ebbel EN, Leymarie N, Schiavo S, Sharma S, Gevorkian S, Hersch S, Matson WR, Costello CE. 2010. Identifcation of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and of-line tandem mass spectrometry. Anal Biochem 399:152-161.
56. Elaut G, Török G, Vinken M, Laus G, Papeleu P, Tourwe D, Rogiers V. 2002. Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 30:1320-1328. (Pubitemid 35397033)
57. Epstein J, Sanderson IR, Macdonald TT. 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103:1545-1557.
58. Ernst IM, Wagner AE, Schuemann C, Storm N, Höppner W, Döring F, Stocker A, Rimbach G. 2010. Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fbroblasts. Pharmacol Res 63:233-240.
59. Fang M, Chen D, Yang CS. 2007. Dietary polyphenols may afect DNA methylation. J Nutr 123 (Suppl 1):223S-228S. (Pubitemid 46052885)
60. Ficner R. 2009. Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem 9:235-240.
61. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193. (Pubitemid 29436325)
62. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. 2010. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 28:3623-3629.
63. Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, Kristiansen G. 2008. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381.
64. Fu S, Kurzrock R. 2010. Development of curcumin as an epigenetic agent. Cancer 116:4670-4676.
65. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921. (Pubitemid 34984414)
66. Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S. 1995. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells. Oncogene 10:1119-1123.
67. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. 2009. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058.
68. Ganapathy V, Tangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, Prasad PD. 2008. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10:193-199.
69. Ganapathy V, Tangaraju M, Prasad PD. 2009. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ter 121:29-40.
70. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. 2005. Neuroprotective efects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563. (Pubitemid 40165021)
71. Gilbert ER, Liu D. 2010. Flavonoids infuence epigenetic-modifying enzyme activity: structure-function relationships and the therapeutic potential for cancer. Curr Med Chem 17:1756-1768.
72. Göttlicher M. 2004. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83 (Suppl 1):S91-S92.
73. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O. 2010. Cancer prevention with natural compounds. Semin Oncol 37:258-281.
74. Gurard-Levin ZA, Kilian KA, Kim J, Bähr K, Mrksich M. 2010. Peptide arrays identify isoform-selective substrates for profling endogenous lysine deacetylase activity. ACS Chem Biol 5:863-873.
75. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ. 2009. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28:88-93.
76. Han SH. 2009. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 5:120-125.
77. Hanai H, Sugimoto K. 2009. Curcumin has bright prospects for the treatment of infammatory bowel disease. Curr Pharm Des 15:2087-2094.
78. Handel AE, Ramagopalan SV. 2010. Is Lamarckian evolution relevant to medicine? BMC Med Genet 11:73.
79. Higdon JV, Delage B, Williams DE, Dashwood RH. 2007. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55:224-236. (Pubitemid 46518152)
80. Hockenbery DM. 2010. Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51:476-489.
81. Hoehle SI, Pfeifer E, Metzler M. 2007. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res 51:932-938. (Pubitemid 47292266)
82. Hogarth P, Lovrecic L, Krainc D. 2007. Sodium phenylbutyrate in Huntington's disease: a dose-fnding study. Mov Disord 22:1962-1964. (Pubitemid 350134213)
83. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. 2010. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood 116:2732-2741.
84. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458. (Pubitemid 34563539)
85. Huber K, Schemies J, Uciechowska U, Wagner JM, Rumpf T, Lewrick F, Süss R, Sippl W, Jung M, Bracher F. 2010. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins). J Med Chem 53:1383-1386.
86. Iciek M, Kwiecien I, Wlodek L. 2009. Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen 50:247-265.
87. Imai S. 2010. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res 62:42-47.
88. Imai S. 2009. SIRT1 and caloric restriction: an insight into possible trade-ofs between robustness and frailty. Curr Opin Clin Nutr Metab Care 12:350-356.
89. Imai S, Guarente L. 2010. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 31:212-220.
90. Iorio MV, Croce CM. 2009. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27:5848-5856.
91. Israelsen WJ, Vander Heiden MG. 2010. ATP consumption promotes cancer metabolism. Cell 143:669-671.
92. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H. 1990. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43:1524-1532.
93. Izzotti A, Larghero P, Balansky R, Pfefer U, Steele VE, De Flora S. 2010. Interplay between histopathological alterations, cigarette smoke and chemopreventive agents in defning microRNA profles in mouse lung. Mutat Res. Oct 23 [Epub ahead of print].
94. Jackson MI, Combs GF Jr. 2008. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11:718-726.
95. Jiang S, Ma X, Huang Y, Xu Y, Zheng R, Chiao JW. 2010. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol 3:48.
96. Jones P, Steinkühler C. 2008. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specifc agents. Curr Pharm Des 14:545-561. (Pubitemid 351516878)
97. Juge N, Mithen RF, Traka M. 2007. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64:1105-1127. (Pubitemid 46684547)
98. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Tomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. 2010. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150:72-82.
99. Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfeld E, Ratain MJ. 2010. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics 20:638-641.
100. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. 2009. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 284:7436-7445.
101. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist J P, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931. (Pubitemid 46218695)
102. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588. (Pubitemid 37169221)
103. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435. (Pubitemid 23318291)
104. Kim DH, Kim M, Kwon HJ. 2003. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110-119. (Pubitemid 36836262)
105. Krainc D. 2010. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol 67:388-392.
106. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, Purgatto E, Ong TP, Moreno FS. 2009. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efcacy of tributyrin, a butyric acid prodrug. Int J Cancer 124:2520-2527.
107. Kwak MK, Kensler TW. 2010. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66-76.
108. Kyrylenko S, Baniahmad A. 2010. Sirtuin family: a link to metabolic signaling and senescence. Curr Med Chem 17:2921-2932.
109. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. 2009. DNA microarray profling of genes diferentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2:67.
110. Lane AA, Chabner BA. 2009. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468.
111. Lawless MW, O'Byrne KJ, Gray SG. 2009. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? Curr Diabetes Rev 5:201-209.
112. Lea MA, Randolph VM. 2001. Induction of histone acetylation in rat liver and hepatoma by organosulfur compounds including diallyl disulfde. Anticancer Res 21:2841-2845. (Pubitemid 33054465)
113. Lea MA, Randolph VM, Hodge SK. 1999a. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971-1976. (Pubitemid 29392764)
114. Lea MA, Randolph VM, Patel M. 1999b. Increased acetylation of histones induced by diallyl disulfde and structurally related molecules. Int J Oncol 15:347-352.
115. Lea MA, Randolph VM, Lee JE, desBordes C. 2001. Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int J Cancer 92:784-789. (Pubitemid 32467365)
116. Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C. 2002. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 43:90-102. (Pubitemid 35387261)
117. Leder A, Leder P. 1975. Butyric acid, a potent inducer of erythroid diferentiation in cultured erythroleukemic cells. Cell 5:319-322.
118. Lee JI, Nian H, Cooper AJ, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT. 2009. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila) 2:683-693.
119. Lee JS, Smith E, Shilatifard A. 2010a. The language of histone crosstalk. Cell 142:682-685.
120. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, Cuervo AM, Yao TP. 2010b. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29:969-980.
121. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS. 2002. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of diferent metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11:1025-1032. (Pubitemid 35192653)
122. Lee WJ, Shim JY, Zhu BT. 2005. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and biofavonoids. Mol Pharmacol 68:1018-1030. (Pubitemid 41345793)
123. Li Y, Li X, Guo B. 2010a. Chemopreventive agent 3,3′- diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 70:646-654.
124. Li Y, Kong D, Wang Z, Sarkar FH. 2010b. Regulation of microRNAs by natural agents: an emerging feld in chemoprevention and chemotherapy research. Pharm Res 27:1027-1041.
125. Li Y, Tollefsbol TO. 2010. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 17:2141-2151.
126. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Tompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfeld JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. 2009. Efect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51.
127. Lü J, Jiang C. 2005. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 7:1715-1727. (Pubitemid 41781770)
128. Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T. 2010. Lysine deacetylases are produced in pancreatic beta cells and are diferentially regulated by proinfammatory cytokines. Diabetologia 53:2569-2578.
129. Ma H, Nguyen C, Lee KS, Kahn M. 2005. Diferential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24:3619-3631. (Pubitemid 40756231)
130. Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW. 2006. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 28:1287-1293.
131. Mariadason JM. 2008. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28-37. (Pubitemid 351540961)
132. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90. (Pubitemid 46087907)
133. Marks PA, Xu WS. 2009. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600-608.
134. Marwick JA, Adcock IM, Chung KF. 2010. Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches. Drugs 70:929-948.
135. Masuoka Y, Shindoh N, Inamura N. 2008. Histone deacetylase inhibitors from microorganisms: the Astellas experience. Prog Drug Res 66:335, 337-335, 359.
136. Matthias P, Yoshida M, Khochbin S. 2008. HDAC6 a new cellular stress surveillance factor. Cell Cycle 7:7-10.
137. Meeran SM, Patel SN, Tollefsbol TO. 2010. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5:e11457.
138. Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, Marwick JA, Chakravarty P, Fletcher D, Whittaker P, Megson IL, Kirkham PA, Rahman I. 2008. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 39:312-323.
139. Mercurio C, Minucci S, Pelicci PG. 2010. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62:18-34.
140. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51. (Pubitemid 43054973)
141. Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S. 2008. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ter 7:1923-1930.
142. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O; German Working Group Trace Elements and Electrolytes in Oncology. 2010. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ter 9:136-141.
143. Murugan RS, Vinothini G, Hara Y, Nagini S. 2009. Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res 29:2301-2305.
144. Myzak MC, Dashwood RH. 2006a. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett 233:208-218. (Pubitemid 43327375)
145. Myzak MC, Dashwood RH. 2006b. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfde, and sulforaphane. Curr Drug Targets 7:443-452. (Pubitemid 43744834)
146. Myzak MC, Ho E, Dashwood RH. 2006. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 45:443-446. (Pubitemid 43865853)
147. Myzak MC, Karplus PA, Chung FL, Dashwood RH. 2004. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64:5767-5774. (Pubitemid 39095576)
148. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. 2007. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 232:227-234. (Pubitemid 46203291)
149. Nian H, Delage B, Ho E, Dashwood RH. 2009a. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfdes: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 50:213-221.
150. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. 2009b. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 30:1416-1423.
151. Nian H, Delage B, Pinto JT, Dashwood RH. 2008. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29:1816-1824.
152. Nilsson AC, Östman EM, Knudsen KE, Holst JJ, Björck IM. 2010. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J Nutr 140:1932-1936.
153. Noureen N, Rashid H, Kalsoom S. 2010. Identifcation of type-specifc anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66:625-633.
154. Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R. 1983. Efect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51:9-14. (Pubitemid 13169565)
155. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173. (Pubitemid 46630509)
156. Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. 2009a. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 18:1605-1617.
157. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. 2009b. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15:91-99.
158. Oger F, Lecorgne A, Sala E, Nardese V, Demay F, Chevance S, Desravines DC, Aleksandrova N, Le Guével R, Lorenzi S, Beccari AR, Barath P, Hart DJ, Bondon A, Carettoni D, Simonneaux G, Salbert G. 2010. Biological and
159. Ohta Y, Suzuki KT. 2008. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol 226:169-177. (Pubitemid 350297344)
160. Oki Y, Issa JP. 2006. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1:169-182.
161. Ortore G, Di Colo F, Martinelli A. 2009. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. J Chem Inf Model 49:2774-2785.
162. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH. 2010. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 10:372-387.
163. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859-863. (Pubitemid 46920134)
164. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY. 2008. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368:318-322.
165. Patra SK, Patra A, Dahiya R. 2001. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287:705-713. (Pubitemid 32912772)
166. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF. 2006. Additive neuroprotective efects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22:40-49.
167. Pinto JT, Lee JI, Sinha R, Macewan ME, Cooper AJ. 2010. Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids. Apr 10 [Epub ahead of print].
168. Pledgie-Tracy A, Sobolewski MD, Davidson NE. 2007. Sulforaphane induces cell type-specifc apoptosis in human breast cancer cell lines. Mol Cancer Ter 6:1013-1021. (Pubitemid 46554571)
169. Poke FS, Qadi A, Holloway AF. 2010. Reversing aberrant methylation patterns in cancer. Curr Med Chem 17:1246-1254.
170. Pool-Zobel BL, Sauer J. 2007. Overview of experimental data on reduction of colorectal cancer risk by inulin-type fructans. J Nutr 137:2580S-2584S. (Pubitemid 350058740)
171. Powolny AA, Singh S V. 2008. Multitargeted prevention and therapy of cancer by diallyl trisulfde and related Allium vegetable-derived organosulfur compounds. Cancer Lett 269:305-314.
172. Rahman I. 2008. Dietary polyphenols mediated regulation of oxidative stress and chromatin remodeling in infammation. Nutr Rev 66 (Suppl 1):S42-S45.
173. Rajendrasozhan S, Yao H, Rahman I. 2009. Current perspectives on role of chromatin modifcations and deacetylases in lung infammation in COPD. COPD 6:291-297.
174. Ramadori G, Coppari R. 2010. Pharmacological manipulations of CNS sirtuins: potential efects on metabolic homeostasis. Pharmacol Res 62:48-54.
175. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. 2010. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28:4507-4512.
176. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. 1977. n-Butyrate causes histone modifcation in HeLa and Friend erythroleukaemia cells. Nature 268:462-464.
177. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jafrey SR, Twiss JL, Ratan RR, Langley B. 2009. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106:19599-19604.
178. Ross SA, Milner JA. 2007. Epigenetic modulation and cancer: efect of metabolic syndrome? Am J Clin Nutr 86:s872-s877.
179. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, Ferrante RJ. 2005. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93:1087-1098. (Pubitemid 40776564)
180. Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R. 2007. Proteome analyses of the growth inhibitory efects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 21:2344-2353. (Pubitemid 350011707)
181. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. 2004. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32:1132-1138. (Pubitemid 39287587)
182. Santini V, Gozzini A, Ferrari G. 2007. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8:383-393.
183. Sattler UG, Hirschhaeuser F, Mueller-Klieser W F. 2010. Manipulation of glycolysis in malignant tumors: fantasy or therapy? Curr Med Chem 17:96-108.
184. Savickiene J, Treigyte G, Vistartaite G, Tunaitis V, Magnusson KE, Navakauskiene R. 2010. C/EBPa and PU.1 are involved in distinct diferentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling. Diferentiation 81:57-67.
185. Schantz M, Erk T, Richling E. 2010. Metabolism of green tea catechins by the human small intestine. Biotechnol J 5:1050-1059.
186. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. 2008. Human HDAC7 harbors a class IIa histone deacetylase-specifc zinc binding motif and cryptic deacetylase activity. J Biol Chem 283:11355-11363.
187. Sekhavat A, Sun JM, Davie JR. 2007. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 85:751-758. (Pubitemid 351198422)
188. Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, Verma A. 2010. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2:654-669.
189. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854. (Pubitemid 39383033)
190. Sies H. 2010. Polyphenols and health: update and perspectives. Arch Biochem Biophys 501:2-5.
191. Silva JP, Wahlestedt C. 2010. Role of sirtuin 1 in metabolic regulation. Drug Discov Today 15:781-791.
192. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. 2010a. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ter 10:935-954.
193. Singh N, Tangaraju M, Prasad PD, Martin PM, Lambert NA, Boettger T, Ofermanns S, Ganapathy V. 2010b. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem 285:27601-27608.
194. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. 2004. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12:1325-1334. (Pubitemid 38900774)
195. Stahl SM. 2010. Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr 15:358-365.
196. Stalmach A, Mullen W, Steiling H, Williamson G, Lean ME, Crozier A. 2010a. Absorption, metabolism, and excretion of green tea favan-3-ols in humans with an ileostomy. Mol Nutr Food Res 54:323-334.
197. Stalmach A, Steiling H, Williamson G, Crozier A. 2010b. Bioavailability of chlorogenic acids following acute ingestion of cofee by humans with an ileostomy. Arch Biochem Biophys 501:98-105.
198. Steward WP, Gescher AJ. 2008. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 52:1005-1009.
199. Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, Yamori T, Tsumoto H, Nakagawa H, Miyata N. 2009. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J Med Chem 52:2909-2922.
200. Suzuki T, Kouketsu A, Matsuura A, Kohara A, Ninomiya S, Kohda K, Miyata N. 2004. Tiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 14:3313-3317. (Pubitemid 38624614)
201. Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N. 2005. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 48:1019-1032. (Pubitemid 40270446)
202. Tangaraju M, Carswell KN, Prasad PD, Ganapathy V. 2009a. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417:379-389.
203. Tangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, Ganapathy V. 2009b. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115:4655-4666.
204. Tsuji Y, Suzuki N, T Suzuki K, Ogra Y. 2009. Selenium metabolism in rats with long-term ingestion of Se-methylselenocysteine using enriched stable isotopes. J Toxicol Sci 34:191-200.
205. Valgimigli L, Iori R. 2009. Antioxidant and pro-oxidant capacities of ITCs. Environ Mol Mutagen 50:222-237.
206. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkühler C, Di Marco S. 2004. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101:15064-15069. (Pubitemid 39391719)
207. Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carfí A, De Francesco R, Steinkühler C, Di Marco S. 2007. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep 8:879-884. (Pubitemid 350001433)
208. Venkitaraman AR. 2010. Modifying chromatin architecture during the response to DNA breakage. Crit Rev Biochem Mol Biol 45:2-13.
209. Verkerk R, Schreiner M, Krumbein A, Ciska E, Holst B, Rowland I, De Schrijver R, Hansen M, Gerhäuser C, Mithen R, Dekker M. 2009. Glucosinolates in Brassica vegetables: the infuence of the food supply chain on intake, bioavailability and human health. Mol Nutr Food Res 53 (Suppl 2):S219.
210. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. 2008a. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 19:587-593.
211. Waldecker M, Kautenburger T, Daumann H, Veeriah S, Will F, Dietrich H, Pool-Zobel BL, Schrenk D. 2008b. Histone-deacetylase inhibition and butyrate formation: fecal slurry incubations with apple pectin and apple juice extracts. Nutrition 24:366-374.
212. Wang D. 2009. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 9:241-256.
213. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW. 2008. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33:375-380.
214. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314.
215. Weng JR, Tsai CH, Kulp SK, Chen CS. 2008. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262:153-163.
216. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. 2010. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485-4491.
217. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. 2010. A phase I/II trial of vorinostat in combination with 5-fuorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 65:979-988.
218. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686-689. (Pubitemid 39061685)
219. Xiao L, Huang Y, Zhen R, Chiao JW, Liu D, Ma X. 2010. Defcient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol 123:71-76.
220. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. 2009. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 125:774-782.
221. Yamasaki M, Omi Y, Fujii N, Ozaki A, Nakama A, Sakakibara Y, Suiko M, Nishiyama K. 2009. Mustard oil in "Shibori Daikon" a variety of Japanese radish, selectively inhibits the proliferation of H-ras-transformed 3Y1 cells. Biosci Biotechnol Biochem 73:2217-2221.
222. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. 2003. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte diferentiation in human hepatoma cells. Int J Cancer 103:572-576. (Pubitemid 36091459)
223. Yang XJ, Seto E. 2008. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206-218. (Pubitemid 351301825)
224. Yap KL, Zhou MM. 2010. Keeping it in the family: diverse histone recognition by conserved structural folds. Crit Rev Biochem Mol Biol 45:488-505.
225. Yoshida H, Sugita K. 1992. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells. Jpn J Cancer Res 83:324-328.
226. Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specifc inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179.
227. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. 2003. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351-2358. (Pubitemid 37236392)
228. Yu J, Auwerx J. 2010. Protein deacetylation by SIRT1: an emerging key post-translational modifcation in metabolic regulation. Pharmacol Res 62:35-41.
229. Zeng H, Botnen JH, Briske-Anderson M. 2010. Deoxycholic acid and selenium metabolite methylselenol exert common and distinct efects on cell cycle, apoptosis, and MAP kinase pathway in HCT116 human colon cancer cells. Nutr Cancer 62:85-92.
230. Zhang Y, Talalay P, Cho CG, Posner GH. 1992. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399-2403.